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Immunotherapeutic strategies involving the induction of
antigen-speciﬁc immune responses depend on accurate delivery
of antigen to professional antigen presenting cells (APCs), such
as dendritic cells (DCs). DCs play a key role in regulating
antigen-speciﬁc immunity. DCs reside in peripheral tissues in
an immature diﬀerentiation state in which they actively sample
their environment for the presence of pathogens. Upon ingestion
of pathogens, DCs mature and migrate throughout the vascular
and lymphatic system to present acquired antigens to T cells
located within lymph nodes. During this process eﬃcient uptake
of antigen by DCs and induction of DC migration to regional
lymph nodes are essential to trigger eﬀective immune responses.1
Currently, DCs loaded ex vivo with tumor antigens are
investigated for their ability to induce antigen-speciﬁc T cell
responses in clinical trials. However, objective clinical responses
are thus far limited to a minority of patients. This might partly be
explained by the low percentage of injected DCs that actually
migrate to the lymph nodes to activate the immune system.2 To
overcome this problem and to reduce the high costs involved
with ex vivo culturing of autologous DCs, vaccination strategies
are developed to speciﬁcally target antigens and maturation
stimuli to DCs in vivo.3 Further development and validation of
such vaccination strategies requires noninvasive imaging meth-
ods to track antigen and DCs in vitro and in vivo.4
Several noninvasive imaging techniques for the in vivo track-
ing of targeted nanostructures and injected DCs have been
reported. They include the use of gamma-radiation-emitting
radionuclides, such as indium-111 oxinate (planar gamma
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ABSTRACT: Dendritic cells (DCs) are key players in the
initiation of adaptive immune responses and are currently
exploited in immunotherapy against cancer and infectious
diseases. The targeted delivery of nanovaccine particles (NPs)
to DCs in vivo is a promising strategy to enhance immune
responses. Here, targeted nanovaccine carriers were generated
that allow multimodal imaging of nanocarrierDC interactions
from the subcellular to the organism level. These carriers were
made of biodegradable poly(D,L-lactide-co-glycolide) harboring
superparamagnetic iron oxide particles (SPIO) and ﬂuores-
cently labeled antigen in a single particle. Targeted delivery was
facilitated by coating the NPs with antibodies recognizing the DC-speciﬁc receptor DC-SIGN. The ﬂuorescent label allowed for
rapid analysis and quantiﬁcation of speciﬁc versus nonspeciﬁc uptake of targeted NPs by DCs compared to other blood cells. In
addition, it showed that part of the encapsulated antigen reached the lysosomal compartment of DCs within 24 h. Moreover, the
presence of ﬂuorescent label did not prevent the antigen from being presented to antigen-speciﬁc T cells. The incorporated SPIO
was applied to track the NPs at subcellular cell organel level using transmission electron microscopy (TEM). NPs were found within
endolysosomal compartments, where part of the SPIO was already released within 24 h. Furthermore, part of the NPs seemed to
localize within the cytoplasm. Ex vivo loading of DCs with NPs resulted in eﬃcient labeling and detection by MRI and did not
abolish cell migration within collagen scaﬀolds. In conclusion, incorporation of two imaging agents within a single carrier allows
tracking of targeted nanovaccines on a subcellular, cellular and possibly organism level, thereby facilitating rational design of in vivo
targeted vaccination strategies.
KEYWORDS: imaging, nanocarriers, biocompatible materials, contrast agents, ﬂuorescence, magnetic resonance imaging,
nanoparticles, dentritic cells
521 dx.doi.org/10.1021/mp100356k |Mol. Pharmaceutics 2011, 8, 520–531
Molecular Pharmaceutics ARTICLE
scintigraphy),4,5 ﬂuorine-18 (PET),6 luciferase (bioluminescence
imaging),7 and iron oxide magnetic nanoparticles (MRI).5,8,9
The signal emanating from the nanoparticle or cell needs to be
combined with anatomical information. Presently, magnetic
resonance imaging (MRI) is among the best noninvasive tech-
niques used in clinical medicine for assessing anatomy and
function of tissues. In addition, MRI oﬀers several advantages
such as excellent temporal and spatial resolution, no direct
exposure to radioactive compounds, rapid in vivo acquisition of
images and a long eﬀective imaging window. Dextran- or
carboxydextran-coated superparamagnetic iron oxide particles
(SPIO) nanoparticles, such as Feridex or Resovist, are the most
commonly used and clinically approved SPIO-based MRI contrast
agents.10,11 For in vivo tracking of particles, diﬀerent approaches
using various coating or encapsulation strategies for iron magnetic
nanoparticles in liposomes or poly(lactide-co-glycolide) (PLGA)
have been reported.1214 However, most approaches lack speciﬁc
targeting signals and thus result in ineﬃcient accumulation of
particles in target cells, thereby hampering detection of cells by
MRI. Although useful at the anatomical level, MRI is much less
sensitive than ﬂuorescence imaging when used to monitor small
tissue lesions, molecular activity, or cellular activities. By the
integration of both MR and optical imaging techniques, the
limitations of each technique can be oﬀset by the other. Therefore,
a combination of ﬂuorescence and SPIO labeling could together
provide essential information to track nanovaccine particles (NPs)
and immunotherapeutic DCs.1519
The development of nanovaccine-based multimodal imaging
contrast agents that speciﬁcally target DCs provide additional
advantages over conventional SPIO-loaded DC vaccines:20,21 (i)
Due to the synergisticmagnetism of themultiple iron oxide particles
present within a single PLGA NP the relaxivity (R2), a measure of
MR contrast, of SPIO encapsulated within PLGANPs is larger than
that of free SPIO;12 (ii) controlled release of antigen from PLGA
enhances immune responses induced by the vaccine;22 (iii) targeted
delivery to DCs should increase the cell speciﬁc uptake of contrast
agents, thereby improving signal intensity in MRI; (iv) the circula-
tion time in blood might be enhanced by the use of PEG-coated
PLGA NPs;23,24 (v) and the multifunctional PLGA NPs should
allow monitoring of DC migration via lymphatic drainage into
lymph nodes in real time by noninvasive MRI techniques, while
internalization and antigen processing can be studied at the cellular
level using ﬂuorescence.
In this study we encapsulated a ﬂuorescent FITC-labeled
peptide antigen and iron oxide within NPs composed of the
biocompatible polymer PLGA. Moreover, an antibody recogniz-
ing the human DC-speciﬁc antigen receptor DC-SIGN was
grafted onto the particle surface to ensure speciﬁc delivery of
NPs to DC.We show that incorporation of FITC-peptide in NPs
was suitable for confocal/ﬂuorescence microscopy and FACS
analysis, while the inclusion of iron oxide nanoparticles allowed
tracking by transmission electron microscopy (TEM) and MRI.
Moreover, the encapsulated peptide antigen was presented to
T cells, indicating imaging results can be directly linked to
immunological outcome.
2. MATERIALS AND METHODS
2.1. Materials and Reagents. PLGA (Resomer RG 502 H,
lactide:glycolide molar ratio 48:52 to 52:48) was purchased from
Boehringer Ingelheim, Germany. Solvents for peptide synthesis
and PLGA preparation (dichloromethane (DCM), 2-propanol,
N,N-dimethylformamide (DMF) and ethyl acetate) were ob-
tained from Sigma-Adrich (The Netherlands). Lipids purchased
from Avanti Polar Lipids (USA) include 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[carboxyl(polyethylene glycol)2000]
(ammonium salt) and 1,2-distearoyl-sn-glycero-3-phosphoethano-
lamine-N-[methoxy(polyethylene glycol)-2000] (ammonium
salt) (mPEG 2000 PE). Iron(III) chloride hexahydrate
(FeCl3 3 6H2O) pure granulated, 99%, iron(II) chloride tetrahy-
drate (FeCl2 3 4H2O) 99%, ammonium hydroxide (5 M), oleic
acid, PEG diamine were purchased from Fisher Scientific (USA).
EDAC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide) and
NHS (N-hydroxisuccinimide) were obtained from Pierce (USA).
The following antibodies were used: anti-human HLA-DR/
DP clone Q5/13,25 Alexa Fluor 647-labeled goat anti-human and
goat anti-mouse IgG (Invitrogen, TheNetherlands). Humanized
anti-DC-SIGN (hD1) and its isotype control (h5G1.1) were
described before26,27 and were kindly provided by Alexion
Pharmaceuticals (USA).
2.2. Peptide Synthesis. The TT epitope comprises the
830844 region of tetanus toxoid. Fluorescein isothiocyanate
(FITC) and TT epitopes were linked by a Lys-Lys cathepsin-like
cleavage site. The peptide antigen (FITC-KKQYIKANSKFIGI-
TELKK) with the extreme N-terminal modified with FITC was
synthesized manually according to standard protocols of solid-
phase peptide synthesis, using the Fmoc/tert-butyl strategy and
CTC resin.28 NR-Fmoc-protected amino acids were incorpo-
rated using 1-hydroxybenzotriazole (HOBt) and N,N0-diisopro-
pylcarbodiimide (DIPCDI) in DMF for 1.5 h and monitored by
Kaiser ninhydrin tests.29 The Fmoc-protecting group was cleaved
with a 20% piperidine solution in DMF (2  10 min). After
completion of the sequence, the peptide-resin was labeled with
FITC (5 equiv) and DIEA (10 equiv) in a 9:1 mixture of DMF:
DCM and then added to the peptide-resin and stirred for 12 h.
The FITC-TT peptide was cleaved from the CTC resin with
TFADCM (1:99). The cleavage solution was removed by
evaporation under reduced pressure. The lateral chains were
completely removed by treatment with TFA:H2O:TES
(95:2.5:2.5 v/v/v) for 2 h. The crude peptide product showed
purity greater than 85% by RP-HPLC.
2.3. Preparation of SPIO and Conjugation of Peptide to
SPIO. SPIO were fabricated as described by Kumar et al. In
brief,30 SPIO were synthesized under inert atmospheric condi-
tions through reduction of FeCl3 and FeCl2 salts using NH4OH
solution at room temperature to obtain a black precipitable of
SPIO. Next, the SPIOwas recovered withmethacrylic acid for 2 h
at 70 C in presence of K2S2O8. SPIOCOOH were purified by
centrifugation and washed several times with water. Subse-
quently, FITC-TTpeptide was covalently attached via amide
bond to the SPIO using carbodiimide at room temperature.
Briefly, SPIO (100 mg/mL) containing carboxyl groups on the
surface were activated with EDAC (10 equiv) and NHS (10 equiv)
for 1 h in the presence of isotonic 0.1 MMES saline buffer pH 5.5.
MES buffer was used for slowing down hydrolysis of theNHS esters
on the SPIO because it lacks amino and carboxyl groups, which
could compete in the reaction. The SPIOwere then recovered using
a magnet, thereby removing excess EDAC/NHS and the water-
soluble isourea byproduct. Activated SPIO were resuspended in
1 mL of PBS buffer and reacted with the amino group at the
C-terminal of the FITC-TTKK for 3 h at room temperature.
Unbound peptide was removed by magnetic separation, and the
FITC-TTSPIO was washed three times with PBS. The unbound
FITC-TT peptide was measured by fluorescence (492 nm
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excitation and 520 nm emission) relative to a standard curve using a
CytoFluor II (Applied Biosystem, Foster City, CA). The amount of
FITC-TT peptide that bound to 1 mg of SPIO was around 50.8(
5.3 μg. The conjugation efficiency was approximately 50%.
2.4. NP Preparation. PLGA NPs with entrapped FITC-TT
peptide conjugated SPIO were prepared using an o/w emulsion
and solvent evaporationextration method.31 In brief, 90 mg
of PLGA in 3 mL of DCM containing the FITC-TTSPIO
(50 mg/mL) were added dropwise to 25 mL of aqueous 2% (w/
v) PVA in distilled water and emulsified for 90 s using a sonicator
(Branson, sonofier 250). A combination of lipids (DSPE-PEG-
(2000)carboxylic acid (6 mg) and mPEG 2000 PE (6 mg)) were
dissolved in DCM and added to the vial. The DCMwas removed
by a stream of nitrogen gas. Subsequently, the emulsion was
rapidly added to the vial containing the lipids and the solution
was homogenized during 30 s using a sonicator. Following
overnight evaporation of the solvent at 4 C, the NPs were
collected by ultracentrifugation at 60000g for 30 min, washed
three times with distilled water and lyophilized.
2.5. Determination of FITCPeptideSPIO Content of the
NPs. FITCpeptideSPIO entrapment efficiency was deter-
mined by digesting 10 mg of NPs in 1 mL of 0.8 mol/L NaOH
overnight at 37 C. The FITCpeptideSPIO was separated by
magnetic field and washed three times with distilled water. The
amount of FITCpeptideSPIO was determined by weighing
after lyophilized samples of the preparation and the FITC
peptideSPIO was also measured by fluorescence relative to
standard curve (492 nm excitation and 520 nm emission) using a
CytoFluor II (Applied Biosystem, Foster City, CA). The amount
of FITCpeptideSPIO encapsulated in 10 mg of PLGA was
around 3.2 ( 0.6 mg of FITCpeptideSPIO.
2.6. Conjugating Antibodies to the NPs. Antibodies were
conjugated to the DSPE-PEG(2000)carboxyl-containing PLGA
NP-FITC-TTSPIO preparation. Subsequently, particles were
activated with EDAC and N-hydroxisuccinimide in MES buffer
(pH 6.0) during 1 h at room temperature. The activated
carboxyl-NP was washed three times with MES buffer by
centrifugation. Subsequently, antibodies (200 μg per mg of
NP) were added and the solution was stirred during 3 h at room
temperature. Unbound antibodies were removed by centrifuga-
tion (10000g, during 10 min) and the NP-hD1 and NP-isotype
were washed three times with PBS. The presence of hD1 and
h5G1.1 on the particle surface was confirmed by staining NPs
with goat anti-human secondary antibodies, followed by analysis
on a FacsCalibur flow cytometer using CellQuest software (BD
Biosciences, USA) (see Supporting Information, Figure S1).
Quantification of antibodies (Abs) on the particle surface was
perfomed by Coomassie dye protein assay (Table 1).32
2.7. Scanning Electron Microscopy (SEM). NP morphology
was studied by SEM. NPs were transferred to metallic stubs with
double-sided conductive tape. Subsequently, samples were ion-
coated with gold with a sputter coater (EDWARDS, Scan coat,
United Kingdom) for 180 s in a vacuum at a current intensity of
40 mA. Samples were analyzed on a Jeol JSM-6310 scanning
electron microscope.
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NP 16.3( 4.1 320( 60 199.4( 6.8 0.111( 0.045 34.9( 3.6
NP-Isot 16.3( 4.1 320( 60 225.6( 12.6 0.117( 0.056 14.5( 4.6 19.3( 1.8
NP-hD1 16.3 ( 4.1 320( 60 227.8( 11.2 0.197( 0.066 12.7( 3.5 18.1( 1.5
aDetermination of FITC-TT peptide, size distribution and zeta potential of PLGA nanoparticles loaded with SPIO. NP-hD1 and NP-isotype and
without Abs were characterized by DLS and zeta potential measurements. Particle size data represent the mean value( SD of dynamic light scattering
data. Zeta potential data represent the mean value ( SD of 5 readings. Change in zeta potential, as well as the increase in sizes and distribution of the
particles, clearly indicates that Abs were eﬃciently conjugated to the PLGA nanoparticles surface. FITC-TT antigen content of PLGA nanoparticles was
determined by particle digestion andmeasuring ﬂuorescence relative to standard curves. Data represent % of encapsulated antigen relative to the amount
of antigen added during particle formation ( SD of experiments performed in triplicate. The amount of antibody introduced onto nanovaccine was
determined by Coomassie dye protein assay and is depicted as the mean ( SD of two experiments.
Figure 1. Schematic illustration of targeted nanovaccine carrier. NPs
were generated containing iron oxide nanoparticles as MRI contrast
agent and FITC as ﬂuorescent label for ﬂow cytometry and confocal
optical imaging purposes. SPIO nanoparticles and FITC-TT peptide,
which was covalently bound to the SPIO nanoparticles, were encapsu-
lated into the PLGA matrix by a single emulsion method. The
nanoparticles were shielded by a combination of PEG-lipid and carboxyl
functionalized PEG-lipid layers. The PEG-lipid prevents nonspeciﬁc
interactions, and the carboxyl functionalized PEG-lipid allows introduc-
tion of antibodies on the PLGA surface.
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2.8. Trasmission Electron Microscopy (TEM).Drops of NPs
and NP-SPIO were deposited over carbon-coated Formvar films
on copper grids and stained with a conventional negative staining
for TEM using 2% uranyl acetate. Samples were analyzed with a
transmission electron microscope (JEOL JEM 1010 (Jeol,
Akishima Tokyo, Japan) at an accelerating voltage of 80 kV.
The images were obtained with a CCD Megaview III (SIS)
camera (M€unster, Germany).
2.9. Dynamic Light Scattering andZeta Potential.Dynamic
light scattering (DLS)measurements onNPs were performed on
an ALV light-scattering instrument equipped with an ALV5000/
600 Multiple Tau Correlator and an Oxxius SLIM-532 150
mWDPSS laser operated at a wavelength of 532 nm. A refractive
index matching bath of filtered cis-decalin surrounded the
cylindrical scattering cell, and the temperature was controlled
at 21.5( 0.3 Cusing a Haake F3-K thermostat. For each sample
Figure 2. Nanovaccine carriers contain multimodal imaging properties. (A) The presence of FITC-TT peptide in the nanovaccine carriers was
conﬁrmed by measuring NPs with (gray, ﬁlled) or without (black line) encapsulated FITC-TT peptide by ﬂow cytometry. (B) NPs containing FITC-
TTSPIO nanoparticles were mounted on glass slides and visualized by confocal laser scanning microscopy. (C) The presence of SPIO inNPs was
conﬁrmed byMRI. The average signal intensity of capillary tubes containing SPIO-labeled NPs (left in the inset image) and NPs without SPIO (right in
the inset image) was determined. A clear reduction in signal intensity was obtained for NPs when SPIO was encapsulated. (D) NP analysis by SEM
revealed nanosized spherical particles. TEM analysis of NPs (E) with and (F) without SPIO. Image analysis revealed the electron-dense SPIO particles
within the PLGA matrix of the NPs and the presence of the PEG-lipid layer surrounding the particles. (Scale bar, 200 nm; magniﬁcation, 40000.)
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the autocorrelation function, g2(τ), was recorded ten times at a
detection angle of 90. For each measurement the diffusion
coefficient, D, was determined using the second order cumulant
and the corresponding particle diameter was calculated assuming
that the particles were spherical in shape. Zeta potential of NPs
was determined on a Malvern ZetaSizer 2000 (U.K.).
2.10. Iron Staining of SPIO within DCs. After incubation of
DCs with NPs-hD1 or NPs-isotype for 24 h, cytospins of these
cells were prepared and air-dried. Prussian blue staining was
performed to detect SPIO within these cells. Slides were stained
with freshly prepared potassium hexacyanoferrate(II) solution
(Sigma, Germany; 2%, with 0.1 N HCl) for 20 min and washed
three times in distilled water. Slides were counterstained with
0.05% nuclear fast red in 5% aluminum sulfate. The samples were
viewed in a Leica DMLB microscope.
2.11. Cells. Granulocytes and peripheral blood mononuclear
cells (PBMCs) were obtained from buffy coats of healthy
individuals and were purified using Ficoll density centrifugation.
Peripheral blood lymphocytes (PBLs) and immature DCs
(iDCs) were obtained from PBMCs as reported elsewhere.26
In brief, PBMCs were allowed to adhere for 1 h at 37 C.
Nonadherent cells (PBLs) were gently removed, washed and
cryopreserved. Adherent monocytes were cultured in the pre-
sence of IL-4 and GM-CSF (500 and 800 U/mL, respectively;
Schering-Plough International, USA) for 6 days to obtain
immature DCs. DCs were cryopreserved until use. Cells were
cultured in X-VIVO 15 medium (Cambrex, Belgium) supple-
mented with 2% human serum.
2.12. Analysis of Uptake and Binding of NP by DCs Using
Flow Cytometry. NP binding was studied by incubating cells
with 20 μg/mL NP-hD1, isotype, or NPs without Abs for 1 h at
4 C in culture medium. Subsequently, cells were washed and
analyzed by flow cytometry. Uptake was studied by incubating
cells with 20 μg/mL NP-hD1, isotype and NPs without Abs at
37 C for 1 h. The cells were washed and analyzed by flow
cytometry on a FacsCalibur (Becton Dickinson, USA).
2.13. Analysis of Uptake and Binding of NP by DCs Using
Confocal Microscopy. Binding and internalization of NPs
containing FITC-TT was confirmed by confocal microscopy.
Experiments were performed as described above for analyzing
binding and uptake by flow cytometry. Subsequently, cells were
fixed on poly-L-lysine coated glass slides and stained with anti-
human MHC class II antibody (clone Q5/13) or IgG2a isotype
control, followed by a secondarymAb goat-anti-mouse Alexa 647
antibody. Cells were imaged with a Bio-Rad MRC 1024 confocal
system operating on a Nikon Optiphot microscope and a Nikon
60 planApo 1.4 oil immersion lenses. Pictures were analyzed
with Bio-Rad Lasersharp 2000 and Adobe Photoshop 7.0 (Adobe
Systems, USA) software.
2.14. Targeting NPs to DCs within a Mixed Blood Cell
Population. Leukocytes isolated from buffy coats were mixed
with DCs in a 20:1 ratio in culture medium. Cells were incubated
with NPs-hD1, isotype, and NPs without Abs (50 μg/mL) at
37 C for 3 h. Cells were washed and stained with a mannose
receptor-specific antibody (clone 19.2, Becton Dickinson) or
isotype control antibody to specifically detect DCs. Subse-
quently, cells were analyzed by flow cytometry on a FacsCalibur.
The cell associated fluorescence was calculated by dividing the
mean cell fluorescence intensity (mfi) for a given sample by the
mfi of DCs incubated with NP-hD1, which was set at 100%.
Figure 3. Analyzing nanovaccine carrier uptake and binding by ﬂuorescence. Binding of various nanovaccine carriers were determined by (A) ﬂow
cytometry and (B) confocal microscopy. NP-hD1, NP-iso and NPs without Abs were incubated with DCs for 1 h at 4 C. DCs cultured in medium
without NPs were included as a negative control. Part of the cells were analyzed by ﬂow cytometry. The remaining cells weremounted on glass slides, and
the cell membrane was stained with an antibody recognizing MHC class II. Cells were analyzed by confocal scanning laser microscopy to visualize
binding of NP-hD1 to DCs. Subsequently, the experiments were repeated at 37 C to study NP uptake by DCs for 1 h using (C) ﬂow cytometry and (D)
confocal analysis. Flow cytometry data represent the mean of experiments performed in triplicate ( SD.
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2.15. Localization of TargetedNPswithinDCs by TEM.The
DCs were incubated with NPs-hD1, isotype or without Abs for
24 h and fixated with 2% glutaraldehyde/0.1 mol/L sodium
cacodylate buffer (pH 7.3). Then, the cells were rinsed in 0.1
mol/L sodium cacodylate buffer, postfixed in 1% OsO4/0.1
mol/L sodium cacodylate buffer, rinsed in 0.1 mol/L sodium
cacodylate buffer and spun down in 2% agar/0.1 mol/L sodium
cacodylate buffer. The cell pellet was cut in small cubes,
dehydrated through graded alcohol and embedded in Agar 100
resin (Agar Scientific Limited, England).
Ultrathin sections were cut on a Leica Reichert Ultracut S
picked up on Formvar coated copper grids, contrasted with
uranyl acetate and lead citrate and examined with a Jeol 1010
transmission electron microscope (Jeol, Akishima Tokyo,
Japan). Images were taken on Imaging plates (Ditabis) or with
a CCD Megaview III (SIS) camera (M€unster, Germany).
2.16. Characterization of SPIO-Containing NPs by MRI.
The presence of SPIO presence inside NPs was analyzed byMRI.
A fixed amount (1 mg) of unlabeled and SPIO labeled NPs were
embedded into 100 μL of agar gel to produce a homogeneous
sample. Each sample was introduced in capillary tubes, and both
tubes were inserted into a 2 mL Eppendorf tube previously filled
with agar gel. The whole sample was imaged in a 7T Clinscan
MRI scanner (Bruker Biospin MRI GmbH, Germany) with a
proton birdcage volume coil. The sample was placed inside the
coil and a turbo spin echo pulse sequence (TE/TR = 7.7/900ms,
0.12  0.12  1 mm resolution, turbo factor = 10) was used to
obtain images.
2.17. Analysis of Uptake of Targeted NPs by DCs Using
MRI. To analyze the uptake of vaccine carriers by DCs, 5  105
DCs were incubated with targeted and untargeted NPs contain-
ing identical amounts of SPIO for 24 h at 37 C in culture
medium. Subsequently, cells were embedded in 200 μL of a
collagen matrix and placed in NMR tubes. Collagen gels were
placed above and below the cells as a positive reference. A turbo
spin echo image (TE/TR = 4.2/900 ms, 0.1  0.1 in plane
resolution, slice thickness = 5mm, turbo factor =10) was taken to
directly compare the uptake of the three different carriers.
2.18. MRI Migration Experiment. A particular type of
phantom was used to study cell migration. Gel scaffolds that
mimic human tissue were specially prepared to track migration of
hDCs labeled with NP-SPIO-hD1. In the bottom of a 2 mL
Eppendorf tube, a 300 μL scaffold layer was inserted as a control
and in order to provide a flat surface for the cell layer. Right above
this layer, 3  106 cells embedded in 200 μL of scaffold gel
layer was placed. On top of this (potential migration region), two
150 μL layers with different CCL21 chemokine concentrations
(40 nmol/L first layer, 80 nmol/L upper layer) were introduced
in order to externally create a chemokine gradient to stimulate
cell migration. Immediately after the whole sample was settled,
the phantom was taken to the 7T MRI scanner to perform a
longitudinal track of the cell migration. Ten consecutive and
Figure 4. Detecting nanovaccine carrier uptake by DCs using MRI and Prussian blue staining. (A) Since ﬂuorescent labels are rapidly exported out of
the cell, prolonged uptake of NPs by DCs was analyzed by MRI. DCs were incubated with NP-hD1, NP-iso and NPs without Abs for 24 h at 37 C to
study uptake by DCs. Subsequently, cells were embedded in collagen and placed in NMR tubes. Collagen gel without cells were positioned above and
below the cells as a positive reference. Inset shows the MR image of the three collagen gels containing cells loaded with the various NPs. Relative SPIO
content of the diﬀerent samples was determined by measuring the average signal intensities of the reference gels and gels containing the DCs. The data
represent mean values of an experiment performed in triplicate ( SD. Histological analysis of DCs incubated with (B) NP-hd1, (C) NP-iso, and (D)
NPs without Abs for 24 h at 37 C. Cells were stained with Prussian blue staining to detect SPIO (blue). Cell nuclei are stained red. Magniﬁcation, 60.
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equivalent gradient echo images (TE/TR = 4/100 ms; flip angle,
25; in plane resolution, 0.16 0.16 mm2; slice thickness, 1 mm)
were taken every 80 min to track potential migration of hDCs
during 13 h approximately.
2.19. Antigen Presentation Assay. iDCs and PBLs of donors
that respond to TT-antigen were obtained from buffy coats after
informed consent. iDCs were incubated with NP-hD1 and
isotype (containing 25 ng to 1 ng of FITC-TT peptide) for 2
days at 37 C. Following washing, the TT-responsive PBLs were
added to the iDCs (1:10 hDC/T cells relationship). Four days
after addition of the PBLs, proliferative responses were deter-
mined by adding tritiated thymidine (1 μCi [0.037 MBq]/well;
MP Biomedicals, Amsterdam, The Netherlands) to the cell
cultures. Tritiated thymidine incorporation was measured after
16 h in a scintillation counter.
3. RESULTS AND DISCUSSION
3.1. Design, Preparation andCharacterization of Targeted
Nanovaccine.To design a NP tomonitor DC-based vaccination
strategies on subcellular, cellular and organism level we generated
NPs containing an optical imaging and a MRI contrast agent
together with antigen. These particles were coated with a DC-
specific antibody to specifically and efficiently load DCs
(Figure 1). The tetanus toxoid (TT) 830844 peptide was used
as a clinically relevant model antigen to study presentation of
nanovaccine-encapsulated antigens. This TT peptide is fre-
quently used as a helper epitope in clinical trials to increase
immune responses by increasing CD4 T cell response.33 In our
case, the TT peptide was covalently linked to the fluorophore,
FITC (FITC-TT), by continuous solid-phase synthesis,34to
allow visualization of incorporated peptide and uptake of PLGA
containing FITC-TT peptide by DCs. The FITC label was
separated from the TT peptide by a cleavage site (-KK-) that is
recognized by the phagosomal/endosomal protease cathepsin,
allowing peptides to be independently processed for presenta-
tion to T cells following NP ingestion.34,35
Furthermore we exploited superparamagnetic SPIO nanopar-
ticles (see Table 1 in the Supporting Information). Initially, SPIO
nanoparticles of 8.2( 1.5 nm in diameter were conjugated to the
peptide via a cleavable linker (-KK-) via an amide bond to allow
separation of the peptide from the SPIO following uptake by
Figure 5. Subcellular tracking of nanovaccine carriers by confocal imaging and TEM. DCs were incubated with targeted nanovaccine (NP-hD1) for 1 h
and chased for 24 h. Subsequently, cells were ﬁxed and analyzed by (A) confocal laser scanning microscopy or (B) TEM. For confocal laser scanning
miscroscopy, DCs were stained for the early endosomal marker EEA1 and the lysosomal marker LAMP1. Following 24 h incubation ﬂuorescence was
still present in cells and mainly localized in the perinuclear area together with LAMP1. Part of the ﬂuorescence also localized to EEA1 and LAMP1
negative sites suggesting targeted nanovaccine may escape from endosomes (arrows). For TEM studies DCs were embedded and analyzed. The NPs
could be distinguished by their morphology from intracellular organelles. Part of the NPs was found in the endocytic vesicles (1). A proportion of the
SPIO was already released from NPs and associated with endosomal or lysosomal membranes (2). Some NPs also appeared to be localized close to, or
within, the vesicle membrane at the endosomal/cytosolic interface (3); other NPs were localized within the cytoplasm (4).
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cells. The conjugation of FITC-TT peptide to SPIO was con-
ﬁrmed by measuring particle-associated ﬂuorescence. A similar
strategy was successfully performed previously by Huang et al. to
conjugate protein to SPIO.36 Next, FITC-TTSPIO was en-
capsulated within the PLGA NPs using a single emulsion
method. The loading eﬃciency of the SPIO in the PLGA NP
was around 58%. The NP surface was coated with a polyethylene
glycol (PEG)-lipid layer to minimize nonspeciﬁc binding to cells
and to allow the incorporation of a DC-speciﬁc anti-DC-SIGN
(hD1) antibody to eﬀectively target DCs. To facilitate both steps,
a combination of unmodiﬁed and PEG-lipids functionalized with
carboxyl groups was introduced on the NP surface. The char-
acteristics of targeted PLGANPs containing SPIO and FITC-TT
peptide (size distribution, polydispersity index, zeta potential,
FITC-TT entrapment eﬃciency, SPIO content and amount of
Abs conjugated to PLGA nanoparticle surface) are shown in
Table 1. Exploiting dynamic light scattering (DLS) to assess the
diﬀerence in size between NPs with and without Abs attached to
the surface, we found that PLGA-NPs without Abs was 199.4 (
3.4 nm in diameter, while the sizes of NP-hD1 and isotype were
225.6 ( 12.6 and 227.8 ( 11.2 nm, respectively. It should be
noted that the conjugation of Abs to the NP alters the size. The
hydrodynamic diameter of the NP increases approximately in
26.2 and 28.4 nm respectively, when the Abs (hD1 and isotype)
were incorporated on the PLGA surface. This increase is in
agreement with the theoretical length of Abs, which is about
13.5 ( 1.5 nm. Flow cytometry conﬁrmed that antibodies were
present on the surface (see Supporting Information, Figure S1).
In addition, the zeta potential of antibody-coated NPs was
considerably less negative than the NPs without Abs (Table 1).
The zeta potential value of noncoated NP-COOH was34.9(
3.6 mV while the values of NP-hD1 and isotype were 14.5 (
4.6 and12.7( 3.5 mV, respectively. This reduction in the zeta
potential reﬂects the conjugation reaction between the carboxyl
group of NPs and the amino groups of the Abs, providing
additional evidence that the Abs were present on the NP surface.
Therefore, conjugation of Abs to NPs alters not only their size
but also particle charge. The amount of antibodies present on the
particle surface was 18.1 ( 1.5 μg per mg of PLGA for hD1 and
19.3( 1.8 μg per mg of PLGA for the isotype control antibody,
as determined by a Coomassie-based protein assay (see Table 1).
All NPs showed a relatively uniform size distribution, which
was reﬂected by low polydispersity indexes (0.117 ( 0.056 and
0.197 ( 0.066, respectively).
3.2. Multimodal Imaging of NPs. To demonstrate that the
NPs could be monitored at the subcellular, cellular and multi-
cellular levels due to its multimodal imaging properties
(fluorescence and magnetic resonance), a combination of various
techniques were used. Flow cytometry and confocal imaging clearly
showed the presence of FITC-TTpeptidewithinNPs (Figure 2A,B),
while the SPIO was detectable by MRI. Figure 2C shows the
average signal intensity of unlabeled and SPIO-labeledNPs in the
image shown in the inset. A significant decrease in the signal
intensity (darkening of the image) was clearly appreciated in
labeled NPs, confirming that SPIO were efficiently incorporated
within PLGA. It is important to note that, even though turbo spin
echo is one of the less sensitive MRI sequences to detect the
presence of iron in water protons, the reduction in signal
intensity was easily visualized. These findings indicate that NPs
containing SPIO are suitable for noninvasive imaging monitor
the distribution of injected NPs that target DCs in vivo, or to
follow migration of ex vivo-loaded DCs after administration.
The multimodal imaging characteristics of the NPs shown in
Figure 2 allow the integration of the advantages of MR and
optical imaging techniques. The low sensitivity of MRI can be
complemented by the sensitive optical imaging modality close to
the external body surface, while noninvasive molecular imaging
in the deep tissue can be obtained using MRI.
The morphology of the NPs was determined by scanning
electronmicroscopy (SEM) (Figure 2D) andTEM (Figure 2E,F).
Figure 6. Speciﬁc interactions of targeted nanovaccine with human
DCs within the whole blood cell population. The various nanovaccines
were incubated with leukocytes and DCs to study selective interactions
with human DCs. Leukocytes and DCs were mixed (ratio 20:1) and
cultured for 2 h at 37 C in the presence of NP-hD1 (black bars), NP-iso
(white bars) or NPs without Abs (gray bars) to study whether DCs are
speciﬁcally targeted within a mixed blood cell population. DCs were
detected by staining cells for mannose receptor expression. The relative
ﬂuorescence of the mannose receptor positive (DC) and negative
(leukocytes) cells were calculated relative to the mean cell ﬂuorescence
of DCs incubated with NP-hD1, which were set at 100%. Data are mean
values ( SD of experiments performed in duplicate.
Figure 7. Speciﬁc targeting of nanovaccine to human DCs enhances
antigen presentation. Presentation of TT peptide was studied by
culturing DCs for 2 days in medium with or without addition of various
concentrations of NP-hD1 (closed circles) or NP-isot (open circles).
Subsequently, autologous TT-responsive PBLs were added. After 4 days,
cellular responses were assessed in a proliferation assay. Data are mean
proliferation indices ( SD relative to medium control for three
experiments.
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This showed that the NPs were spherical in shape, while TEM
analysis revealed the SPIO present within the particle
(Figure 2E). In addition, TEM imaging revealed the presence
of the PEG-lipid layer on the NPs.
3.3. Specific Binding and Uptake of the NPs by DC for ex
Vivo Labeling. To demonstrate one of the advantages of using
fluorescent imaging agents we used the fluorescent properties of
our NPs to quantify specific binding and uptake following
targeted delivery to DCs. NPs coated with hD1 antibody did bind
to DCs, while NPs with isotype control or no antibodies did hardly
bind (Figure 3A). Confocal microscopy confirmed that the NPs
carrying hD1 antibody were attached to the cell membrane of DCs
(Figure 3B). These data showed that targetedNPsmainly bindDCs
via DC-SIGN and not through nonspecific interactions resulting
from the surface charge or Fc receptor binding.
The capacity of the DC-targeted NPs to deliver its contents
inside the cell was investigated by ﬂow cytometry, confocal
imaging, Prussian blue staining and MRI. After 1 h at 37 C,
the uptake of NPs-hD1 (62%) was higher than the correspond-
ing NPs-isotype control antibody (15%) or no antibody (11%)
according to FACS analysis (Figure 3C). These ﬁndings were
conﬁrmed by confocal imaging and showed that NPs were
indeed internalized by the DC rather than simply binding the
cell surface (Figure 3D).
The MR properties of our nanovaccines can be exploited for
noninvasive imaging to monitor the migration of targeted DCs
in vivo or ex vivo loaded. However, MRI sensitivity depends on
the ability to label cells with suﬃcient quantities of SPIO to allow
detection. To address this issue, we incubated human DCs for a
prolonged period of time, 24 h, with high concentrations of targeted
and untargeted NPs. Diﬀerences in cellular uptake of the various
NPs were measured by MRI and conﬁrmed via Prussian blue
staining. In line with the ﬂow cytometry data obtained in the
experiments shown in Figure 3C following 1 h of uptake, a
signiﬁcant increase in uptake of NPs-hD1 by DCs was also detected
after 24 h when compared to uptake of isotype control NPs and
noncoated NPs (Figure 4A). The average signal intensities for the
diﬀerent regions of the image (inset in Figure 4A) are shown.
The ability to detect SPIO-labeled DCs by histological analysis
is important to visualize the intra lymph node or tissue localiza-
tion of DCs following therapy and will, for example, allow us to
assess whether DC-vaccines used in clinical trials are able to reach
the T cell areas of the lymph node.37
Therefore, we assessed whether the presence of SPIO contain-
ing NPs could be detected in DCs by histological analysis using
Prussian blue staining to detect iron. The DC were loaded with
targeted and untargeted NPs and incubated during 24 h. Prussian
blue staining conﬁrmed that NPs containing iron oxide nano-
particles were internalized byDCs (Figure 4BD). In agreement
with ﬂow cytometry and MRI data DCs treated with NP-hD1
showed more intense staining for iron than DCs exposed to NP-
isotype and NPs without Abs.
In conclusion, the intracellular uptake of NPs was conﬁrmed
by confocal imaging and Prussian blue staining. Furthermore,
uptake was evaluated semiquantitatively by ﬂow cytometry and
MRI. Consistent results were obtained by the various techniques,
showing there was a signiﬁcant increase in nanovaccine uptake by
the DC-speciﬁc hD1 antibody.
3.4. Intracellular Localization Detected by Confocal Ima-
ging and Transmission Electron Microscopy. Next, we
exploited the multimodal properties of our NPs to track and
localize their routing inside DCs. Adherent DCs were loaded
with NPs for 1 h and incubated for another 24 h. Subsequently,
DCs were stained for the early endosomal marker EEA1 and the
late endosomal/lysosomal marker LAMP1 to visualize the
various components of the endosomal system (Figure 5A).
Figure 8. Tracking migration of nanovaccine-labeled human DCs in scaﬀolds. (A) Schematic overview of the experimental setup. Diﬀerence images
between diﬀerent time points are shown in (B) 0 h to 6.7 h, (C) 6.7 h to 13 h, and (D) 0 h to 13 h. The upper brighter horizontal bands in these images
clearly reveal upward migration. (E) The average signal intensity in the migration region was determined at various time points. Data are mean signal
intensity ( SD for two experiments.
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NP-derived fluorescence did not colocalize with EEA1 but partly
overlapped with LAMP1 positive compartments indicating that
NPs reached the site where degraded antigens are loaded onto
major histocompatibility class II for presentation. However, part of
the fluorescence localized neither to EEA1 nor to LAMP1 positive
compartments. This could indicate that some particles escaped from
the endosomal pathway. Indeed, it was suggested before those
PLGA particles are able to cross the endosomal membrane and
deliver encapsulated antigen into the cytoplasm.38,39
Additional information about the intracellular fate of the NPs
was obtained by electron microscopy, using the encapsulated
iron as a contrast agent. Electron dense SPIO structures could be
seen in DCs exposed to NP-hD1 and not in control DCs,
showing PLGA is detected by TEM (Figure 5B). SPIO appeared
more electron dense than PLGA and could be detected within
PLGA NP structures. Intact NPs containing SPIO and that were
not obviously surrounded by an additional bilayer other than the
one representing the PEG layer were detected in the cytosol of
DCs. This suggests that part of the NPs escaped from endosomal
compartments.38 In addition, some NPs were localized within
endosomal structures. Unexpectedly, we also detected some free
SPIO associated with endosomal membranes, suggesting SPIO
had already been released from the carrier and preferentially
associated with membrane structures.
Taken together, by using confocal imaging and TEM, it was
possible to demonstrate that targeted SPIO and FITC labeled
NPs are internalized into endosomal compartments within DCs.
Whereas confocal analysis was useful to identify the nature of the
endosomal compartments containing the ﬂuorescent vaccine,
TEM suggested that part of the vaccine carriers had escaped into
the cytosol. The results also showed that 24 h after particle
uptake some SPIO had already been released, while the rest
remained within the carrier, which is in agreement with the slow
degradation process of the PLGA polymer.40 These slow release
characteristics should be favorable for both antigen presentation
and the ability to track DCs by MRI over a prolonged period
of time.
3.5. Determining Specificity of Targeted NPs for DCs. To
further explore the efficiency of targeted delivery of our vaccine
carrier in a more complex system we used the fluorescent
properties of NPs to determine the specificity by which NPs
were taken up by DCs and other cells. To mimic the situation
when targeted NPs are injected into the bloodstream, we
determined the effectiveness of targeting NPs to DCs within a
mixed blood cell population. Monocyte-derived human DCs
were added to leukocytes isolated from whole blood in a ratio of
1:20. NPs targeted to DC-SIGN were more effectively inter-
nalized by DCs than untargeted controls (Figure 6). These
results showed that NPs by themselves passively target to DCs,
which is enhanced by engrafting DC-specific antibodies on the
particle surface.
3.6. FluorophorePeptide Antigen Conjugate Is Pro-
cessed by DCs and Presented to T Cells. Antigen presentation
studies were performed to determine whether the multimodal
imaging strategy was compatible with antigen presentation. DCs
from donors that respond to TT-antigen were exposed to
targeted and untargeted NPs and incubated with autologous T
cells. Despite the presence of SPIO and the fact that FITC was
linked to the peptide antigen, DCs were capable of presenting the
encapsulated antigen to T cells, resulting in T cell proliferation
(Figure 7). Particles coated with hD1 induced T cell proliferation
in a dose dependent fashion, whereas the isotype control coated
NPs did not induce T cell proliferation at the tested concentra-
tions. These results are in agreement with our previous data,
showing enhanced antigen presentation following targeted de-
livery of antigen to DC-SIGN.31
3.7. MRI Tracking of DC Migration. Finally, to evaluate the
migration and tracking of human DCs loaded with NP-hD1,
collagen scaffolds were used to mimic human tissue. The
experimental setup is schematically plotted in Figure 8A. In the
bottom part of a 2 mL eppendorf tube, a scaffold layer was
inserted to provide a flat surface onto which DCs embedded in a
second scaffold gel layer were placed. Above the DC layer, the
potential migration region was applied, consisting of two layers
with different chemokine concentrations. This setup should
generate a gradient triggering DC migration in the direction of
the chemokine. Immediately after the whole sample was settled,
the tube was analyzed in a 7TMRI scanner to longitudinally track
cell migration. Ten consecutive and equivalent gradient echo
images were taken every 80 min to track DC migration for 13 h.
Figures 8BD show the diﬀerence images (1st5th,
5th10th, and 1st10th) corresponding to 0 h to 6.7 h, 6.7 h
to 13 h, and 0 h to 13 h time windows. These images were
generated in order to readily visualize relocalization of the
contrast agent within the collagen scaﬀold. The migration region
can easily be distinguished as a thick band in the upper part of the
sample. The very intense and thin line below the migration
region corresponds to random susceptibility artifacts typical of
regions with high density of SPIO particles. A signal increase with
time in the migration region clearly indicates that DCs had
migrated upward.
Figure 8E shows the evolution of the signal intensity in the
migration region during the whole experiment. The data clearly
show that DCs migrated toward regions containing high che-
mokine levels. Migration was more pronounced during the ﬁrst
part of the experiment, then decreased and eventually stopped.
This is possibly related to cell death during the experiment due to
factors such as lack of oxygen and nutrients and changes in
temperature.
Two conclusions can be drawn from this experiment. First,
ex vivo cultured human DCs were eﬃciently labeled with our
targeted multimodal NPs and allowed tracking of cell migration.
Second, the NPs did not abolish DCmigration toward chemokines,
which is important forDCmigration toward the lymphnodeswhere
they present antigen to T cells and induce immune responses.
4. CONCLUSIONS
We developed a nanovaccine consisting of a biocompatible
polymer containing SPIO and FITC-labeled peptide antigen as a
multimodal imaging contrast agent. We demonstrated that SPIO
was successfully encapsulated within our targeted NPs, conﬁrm-
ing the results of a recent study by Lee and co-workers showing
successful entrapment of SPIO within PLGA.41 Coating NPs
with DC-speciﬁc DC-SIGN Abs signiﬁcantly increased SPIO
uptake as compared to untargeted controls in vitro. At the same
time, the ﬂuorophore allowed quantitative analysis of binding
and internalization by cells by ﬂow cytometry and allowed
identiﬁcation of the endosomal compartments containing the
vaccine by confocal analysis. SPIO was useful for tracking NP
uptake and migration of DCs by MRI in a 3D context as an
artiﬁcial tissue. Together, this identiﬁes PLGA NPs as biocom-
patible vaccine carriers that allow tracking by ﬂuorescence and
MRI without loss of vaccine function. As such, these targeted
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NPs constitute a valuable tool for optimizing DC-based vaccine
therapeutics. These NPs could be used to track current DC
vaccines based on cells that are loaded with antigen ex vivo
following readministration into patients, but also to evaluate
in vivo antibody-mediated DC targeting strategies in preclinical
studies. The ability to track targeted NPs at the subcellular,
cellular and organism levelmake it a valuable tool to study diverse
processes such as receptor biology, antigen processing and
presentation, biodistribution of targeted vaccines and DCmigra-
tion. Thereby, these NPs open up novel possibilities in nano-
medicine to design intelligent vaccines that enter the appropriate
cellular compartment and induce DC activation and migration to
prompt the most optimal immune response.
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